期刊文献+

交叉配合试验在肿瘤患者血小板输注中的临床应用 被引量:1

Clinical application of cross matching in platelet transfusion of patients with tumor
在线阅读 下载PDF
导出
摘要 目的探讨血小板交叉配合试验对肿瘤患者血小板输注效果的临床价值。方法选择39例血小板相关抗体阳性的肿瘤患者,分为随机输注组与交叉配合输注组,计算输注后1h和24h血小板增加校正指数(CCI),判断血小板输注效果并进行比较分析。结果随机输注组与交叉配合输注组的1、24hCCI分别为(6.34±1.82)、(3.05±1.42)×109/L与(15.58±3.12)、(8.13±2.55)×109/L,差异有统计学意义(P<0.05);血小板输注有效率分别为23.81%、83.33%与14.29%、72.22%,差异有统计学意义(P<0.05)。结论对血小板相关抗体阳性的肿瘤患者进行输注前交叉配型可显著提高血小板输注的有效性。 Objective To investigate the clinical value of platelet cross matching for platelet transfusion in patients with tumor.Methods A total of 39 cases of patients with tumors and platelet associated antibody-positive were randomly divided into a random transfusion group and cross-matched transfusion group,corrected count increment(CCI)of platelet of 1hand 24 hafter transfusion were calculated,platelet transfusion effect was determined and compared.Results CCI of 1hand 24 hafter the transfusion in the randomized transfusion group were(6.34±1.82)×109/L and(3.05±1.42)×109/L respectively,and which of cross-matched transfusion group were(15.58±3.12)×109/L and(8.13±2.55)×109/L,the differences were statistically significant(P〈0.05).Efficiency rates of platelet transfusion were 23.81% and 83.33%,14.29% and 72.22%,the differences were statistically significant(P〈0.05).Conclusion The efficiency of platelet transfusion can be increased significantly in patients with tumors and platelet associated antibody-positive before transfusion by platelet cross matching.
出处 《国际检验医学杂志》 CAS 2016年第21期2976-2977,2982,共3页 International Journal of Laboratory Medicine
基金 湖北民族学院附属民大医院2014年度科研项目(MDYY201409)
关键词 交叉配合试验 血小板输注 肿瘤 cross matching platelet transfusion tumor
作者简介 石天,男,技师,主要从事临床输血治疗方面的研究。
  • 相关文献

参考文献10

二级参考文献112

  • 1刘达庄,陆萍,王健莲,包于勤,吴国光.血小板特异性抗体(Sib^a抗体)的研究[J].中华血液学杂志,1995,16(3):115-117. 被引量:21
  • 2范厚臻.血小板抗体检测的意义与方法学进展[J].中国全科医学,2006,9(10):856-857. 被引量:11
  • 3尤建国,李玉峰,汪承亚.血小板输注无效及干预措施的研究进展[J].国际输血及血液学杂志,2006,29(6):499-502. 被引量:28
  • 4Palo R, Capraro L, Hanhela R, et al. Platelet transfusions in adult patients with particular reference to patients undergoing surgery[J]. Transfus Med,2010,20( 1 ) : 30-37.
  • 5Chockalingam P, Sacher RA. Management of patients refractory to platelet transfusion[J]. J Infus Nurs, 2007,30(4) :220-225.
  • 6Verdichio-Moraes CF, Toralles-Pereira C, Grotto RM, et al. Al- lelic frequencies of HPA-1 to 5 human platelet antigen in pa- tients infected with hepatitis C virus [J]. J Med Virol, 2009, 81 (4) :757-759.
  • 7Abboud N, Amin H, Ghazouani L, et al. Polymorphisms of hu- man platelet alloantigens HPA-1 and HPA-2 associated with severe coronary artery disease [J]. Cardiovasc Pathol, 2010, 19 (5) :302-307.
  • 8Blajchman MA. The clinical benefits of the leukoreduction of blood products [J]. J Trauma Inj Infect Crit Care, 2006, 60 (6 Suppl) : S83 -90.
  • 9Fadeyi EA, Adams S, Sheldon S, et al. A preliminary comparison of the prevalence of transfusion reactions in recipients of platelet components from donors with and without human leukocyte anti- gen antibodies [ J ]. Vox Sang, 2008,94(4) : 324-328.
  • 10Droog W, van Thiel SW, Sleeswijk VSR, et. al. Complications due to transfusion-related acute lung injury[J]. Obstet Gynecol, 2009,113 (2 Pt 2) : 560-563.

共引文献112

同被引文献8

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部